CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
08 févr. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 janv. 2024 07h15 HE
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 déc. 2023 09h15 HE
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
09 nov. 2023 16h15 HE
|
CytoSorbents
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
27 oct. 2023 07h00 HE
|
CytoSorbents
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
CytoSorbents to Present at the 8th Annual Dawson James Conference
05 oct. 2023 07h00 HE
|
CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
27 sept. 2023 07h00 HE
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
19 sept. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
11 sept. 2023 11h32 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...